Compare VIAV & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIAV | IOVA |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 1.7B |
| IPO Year | 1996 | 2008 |
| Metric | VIAV | IOVA |
|---|---|---|
| Price | $35.19 | $10.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $32.66 | $9.00 |
| AVG Volume (30 Days) | 3.6M | ★ 13.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,518,300,000.00 | N/A |
| Revenue This Year | $37.78 | $47.74 |
| Revenue Next Year | $10.64 | $40.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.03 | N/A |
| 52 Week Low | $12.05 | $1.76 |
| 52 Week High | $60.43 | $10.98 |
| Indicator | VIAV | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 72.59 |
| Support Level | $34.83 | $3.57 |
| Resistance Level | $35.61 | N/A |
| Average True Range (ATR) | 1.83 | 0.47 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 30.46 | 72.29 |
Viavi Solutions Inc is a world-wide leader in test and measurement and optical technologies. Its test and measurement, and resilient Position, Navigation and Timing (PNT) solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, it develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets. The company's segments are Network and Service Enablement (NSE); and Optical Security and Performance Products (OSP). Majority of revenue comes from NSE segment. It has presence in Americas, Asia-Pacific, and EMEA. Majority of revenue is from America.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.